Select Publications
- Gilbert PB, DeGruttola V, Hammer S. Efficient trial designs for studying combination antiretroviral treatments in patients with various resistance profiles. J Infect Dis. 1998;178(2):340-8.
- Gilbert PB, Self SG, Ashby MA. Statistical methods for assessing differential vaccine protection against human immunodeficiency virus types. Biometrics. 1998;54(3):799-814.
- Gilbert PB, Lele SR, Vardi Y. Maximum likelihood estimation in semiparametric selection bias models with application to AIDS vaccine trials. Biometrika. 1999;86(1):27-43.
- Gilbert PB. Large sample theory of maximum likelihood estimates in semiparametric biased sampling models. Annals of Statistics. 2000;28(1):151-94.
- Gilbert PB, DeGruttola V, Hammer SM, Kuritzkes DR. Virologic and regimen termination surrogate end points in AIDS clinical trials. JAMA. 2001;285(6):777-84.
- Gilbert PB, Novitsky VA, Montano MA, Essex M. An efficient test for comparing sequence diversity between two populations. J Comput Biol. 2001;8(2):123-39.
- Gilbert PB, Self S, Rao M, Naficy A, Clemens J. Sieve analysis: Methods for assessing from vaccine trial data how vaccine efficacy varies with genotypic and phenotypic pathogen variation. J Clin Epidemiol. 2001;54(1):68-85.
- Gilbert PB, Wei LJ, Kosorok MR, Clemens JD (2002). Simultaneous inferences on the contrast of two hazard functions with censored observations. Biometrics
- Gilbert PB, Bosch RJ, Hudgens MG. Sensitivity analysis for the assessment of causal vaccine effects on viral load in HIV vaccine trials. Biometrics. 2003;59(3):531-41.
- Gilbert PB, DeGruttola V, Hudgens MG, Self SG, Hammer SM, and Corey L (2003). What constitutes efficacy for a Human Immunodeficiency Virus vaccine that ameliorates viremia: Issues involving surrogate endpoints in Phase 3 trials. Journal of Infectious Diseases, 188, 179-193
- Gilbert PB. A modified false discovery rate multiple-comparisons procedure for discrete data, applied to human immunodeficiency virus genetics. Journal of the Royal Statistical Society Series C-Applied Statistics. 2005;54:143-58.
- Gilbert PB, Ackers ML, Berman PW, Francis DP, Popovic V, Hu DJ, Heyward WL, Sinangil F, Shepherd BE, Gurwith M. HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine. J Infect Dis. 2005;192(6):974-83.
- Gilbert PB, Peterson M, Follmann D, Francis D, Gurwith M, Heyward W, Hudgens M, Jobes D, Popovic V, Self S, Sinangil F, Burke D, Berman P (2005). Immunologic responses to rgp120 vaccine correlate with the incidence of HIV-1 infection in a Phase 3 preventive HIV-1 vaccine trial. Journal of Infectious Diseases, 191, 666-677.
- Gilbert PB, Sun Y (2005). Failure time analysis of HIV vaccine effects on viral load and
antiretroviral therapy initiation. Biostatistics, 6, 374-394
- Gilbert PB, Rossini AJ, Shankarappa R. Two-sample tests for comparing intra-individual genetic sequence diversity between populations. Biometrics. 2005;61(1):106-17.
- Gilbert P, Novitsky V, Essex M. Covariability of selected amino
acid positions for HIV type 1 subtypes C and B.
AIDS Research and Human Retroviruses, 2005, 21, 1016-1030
- Qin L, Gilbert PB, Corey L, McElrath MJ, Self SG. A framework for assessing immunological correlates of protection in vaccine trials. J Infect Dis. 2007;196(9):1304-12.
- Shepherd BE, Gilbert PB, Lumley T. Sensitivity analyses comparing time-to-event outcomes existing only in a subset selected postrandomization. J Am Stat Assoc. 2007;102(478):573-82.
- Gilbert PB, Hudgens MG. Evaluating candidate principal surrogate endpoints. Biometrics. 2008;64(4):1146-54.
- Gilbert PB, McKeague IW, Sun Y. The 2-sample problem for failure rates depending on a continuous mark: an application to vaccine efficacy. Biostatistics. 2008;9(2):263-76.
- Gilbert PB, Qin L, Self SG. Evaluating a surrogate endpoint at three levels, with application to vaccine development. Stat Med. 2008;27(23):4758-78.
- Gilbert PB, Wu C, Jobes DV. Genome scanning tests for comparing amino acid sequences between groups. Biometrics. 2008;64(1):198-207.
- Gilbert PB, Sato A, Sun X, Mehrotra DV. Efficient and robust method for comparing the immunogenicity of candidate vaccines in randomized clinical trials. Vaccine. 2009;27(3):396-401.
- Sun Y, Gilbert PB, McKeague IW. Proportional hazards models with continuous marks. Ann Stat. 2009;37(1):394-426.
- Gilbert PB. Some design issues in phase 2B vs phase 3 prevention trials for testing efficacy of products or concepts. Stat Med. 2010;29(10):1061-71.
- Gilbert PB, Jin Y. Semiparametric estimation of the average causal effect of treatment on an outcome measured after a postrandomization event, with missing outcome data. Biostatistics. 2010;11(1):34-47.
- Gilbert PB, Wang M, Wrin T, Petropoulos C, Gurwith M, Sinangil F, D'Souza P, Rodriguez-Chavez IR, Decamp A, Giganti M, Berman PW, Self SG, Montefiori DC. Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccin. J Infect Dis. 2010;202(4):595-605.
- Wolfson J, Gilbert PB. Statistical identifiability and the surrogate endpoint problem, with application to vaccine trials. Biometrics. 2010;66(4):1153-61.
- Gilbert PB, Berger JO, Stablein D, Becker S, Essex M, Hammer SM, Kim JH, Degruttola VG. Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: A case study for statistical issues in efficacy trials. J Infect Dis. 2011;203(7):969-75.
- Gilbert PB, Grove D, Gabriel E, Huang Y, Gray G, Hammer SM, Buchbinder SP, Kublin J, Corey L, Self SG. A sequential Phase 2b trial sesign for evaluating vaccine efficacy and immune correlates for multiple HIV vaccine regimens. Statistical Communications in Infectious Diseases. 2011;3.
- Gilbert P, Hudgens M, Wolfson J. Commentary on Judea Pearl's Principal Stratification: A Goal or a Tool? International Journal of Biostatistics. 2011; 7(1)
- Dai JY, Gilbert PB, Masse BR. Partially hidden Markov model for time-varying principal stratification in HIV prevention trials. Journal of the American Statistical Association. 2012;107(497):52-65.
- Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, Liao HX, DeVico AL, Lewis GK, Williams C, Pinter A, Fong Y, Janes H, DeCamp A, Huang Y, Rao M, Billings E, Karasavvas N, Robb ML, Ngauy V, de Souza MS, Paris R, Ferrari G, Bailer RT, Soderberg KA, Andrews C, Berman PW, Frahm N, De Rosa SC, Alpert MD, Yates NL, Shen X, Koup RA, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Rerks-Ngarm S, Michael NL, Kim JH. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med. 2012;366(14):1275-86.
- Plotkin SA, Gilbert PB. Nomenclature for immune correlates of protection after vaccination. Clin Infect Dis. 2012;54(11):1615-7.
- Rolland M*, Edlefsen PT*, Larsen BB, Tovanabutra S, Sanders-Buell E, Hertz T, deCamp AC, Carrico C, Menis S, Magaret CA, Ahmed H, Juraska M, Chen L, Konopa P, Nariya S, Stoddard JN, Wong K, Zhao H, Deng W, Maust BS, Bose M, Howell S, Bates A, Lazzaro M, O'Sullivan A, Lei E, Bradfield A, Ibitamuno G, Assawadarachai V, O'Connell RJ, deSouza MS, Nitayaphan S, Rerks-Ngarm S, Robb ML, McLellan JS, Georgiev I, Kwong PD, Carlson JM, Michael NL, Schief WR, Gilbert PB*, Mullins JI*, Kim JH*. Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature. 2012;490(7420):417-20 (*contributed equally).
- Juraska M, Gilbert PB. Mark-specific hazard ratio model with multivariate continuous marks: An application to vaccine efficacy. Biometrics, in press.
- Huang Y, Gilbert PB, Wolfson J. Design and estimation for evaluating principal surrogate markers in vaccine trials. Biometrics, in press.
- Gilbert PB, Shepherd BE, Hudgens MG. Sensitivity analysis of per-protocol time-to-event treatment efficacy in randomized trials. Journal of the American Statistical Association, in press.